Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Year of publication
Document Type
- Doctoral Thesis (11)
- Journal article (10)
Keywords
- receptor (21) (remove)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (6)
- Medizinische Klinik und Poliklinik I (3)
- Graduate School of Life Sciences (2)
- Institut für Klinische Neurobiologie (2)
- Institut für Virologie und Immunbiologie (2)
- Julius-von-Sachs-Institut für Biowissenschaften (2)
- Institut für Molekulare Infektionsbiologie (1)
- Institut für Pharmakologie und Toxikologie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
EU-Project number / Contract (GA) number
- 201099 (1)
NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic inflammatory myopathies (IIM) and have been proposed as specific therapeutic targets. However, the mechanisms underlying T cell-mediated progressive muscle destruction in IIM remain to be elucidated. We here determined the involvement of the NKG2D - IL-15 signaling pathway. Primary human myoblasts expressed NKG2D ligands, which were further upregulated upon inflammatory stimuli. In parallel, shedding of the soluble NKG2D ligand MICA (sMICA) decreased upon inflammation potentially diminishing inhibition of NKG2D signaling. Membrane-related expression of IL-15 by myoblasts induced differentiation of naive CD8\(^+\) T cells into highly activated, cytotoxic \(CD8^+NKG2D^{high}\) T cells demonstrating NKG2D-dependent lysis of myoblasts in vitro. \(CD8^+NKG2D^{high}\) T cell frequencies were increased in the peripheral blood of polymyositis (PM) patients and correlated with serum creatinine kinase concentrations, while serum sMICA levels were not significantly changed. In muscle biopsy specimens from PM patients expression of the NKG2D ligand MICA/B was upregulated, IL-15 was expressed by muscle cells, CD68\(^+\) macrophages as well as CD4\(^+\) T cells, and \(CD8^+NKG2D^+\) cells were frequently detected within inflammatory infiltrates arguing for a local signaling circuit in the inflammatory muscle milieu. In conclusion, the NKG2D - IL-15 signaling pathway contributes to progressive muscle destruction in IIM potentially opening new therapeutic avenues.
Background: CEACAM3 is a granulocyte receptor mediating the opsonin-independent recognition and phagocytosis of human-restricted CEACAM-binding bacteria. CEACAM3 function depends on an intracellular immunoreceptor tyrosine-based activation motif (ITAM)-like sequence that is tyrosine phosphorylated by Src family kinases upon receptor engagement. The phosphorylated ITAM-like sequence triggers GTP-loading of Rac by directly associating with the guanine nucleotide exchange factor (GEF) Vav. Rac stimulation in turn is critical for actin cytoskeleton rearrangements that generate lamellipodial protrusions and lead to bacterial uptake.
Principal Findings: In our present study we provide biochemical and microscopic evidence that the adaptor proteins Nck1 and Nck2, but not CrkL, Grb2 or SLP-76, bind to tyrosine phosphorylated CEACAM3. The association is phosphorylation-dependent and requires the Nck SH2 domain. Overexpression of the isolated Nck1 SH2 domain, RNAi-mediated knock-down of Nck1, or genetic deletion of Nck1 and Nck2 interfere with CEACAM3-mediated bacterial internalization and with the formation of lamellipodial protrusions. Nck is constitutively associated with WAVE2 and directs the actin nucleation promoting WAVE complex to tyrosine phosphorylated CEACAM3. In turn, dominant-negative WAVE2 as well as shRNA-mediated knock-down of WAVE2 or the WAVE-complex component Nap1 reduce internalization of bacteria.
Conclusions: Our results provide novel mechanistic insight into CEACAM3-initiated phagocytosis. We suggest that the CEACAM3 ITAM-like sequence is optimized to co-ordinate a minimal set of cellular factors needed to efficiently trigger actin-based lamellipodial protrusions and rapid pathogen engulfment.
The aim of current work was contribution to the long-term ongoing project on developing human IL-5 agonists/antagonists that intervene with or inhibit IL-5 numerous functions in cell culture and/or in animal disease models. To facilitate design of an IL-5 antagonist variant or low-molecular weight mimetics only capable of binding to the specific receptor alpha chain, but would lack the ability to attract the receptor common β-chain and thus initiate receptor complex activation it is necessary to gain the information on minimal structural and functional epitopes. Such a strategy was successfully adopted in our group on example of Interleukin 4. To precisely localize minimal structural epitope it is essential to have structure of the ligand in its bound form and especially informative would be structure of complex of the ligand and its specific receptor alpha chain. For this purpose large quantities (tens of milligrams), retaining full biological activity IL-5 and extracellular domain of IL-5 specific receptor α-chain were expressed in a bacterial expression system (E.coli). After successful refolding proteins were purified to 95-99% Stable and soluble receptor:ligand complex was prepared. Each established purification and refolding procedures were subjected to optimization targeting maximal yields and purity. Produced receptor:ligand complex was applied to crystallization experiments. Microcrystals were initially obtained with a flexible sparse matrix screening methodology. Crystal quality was subsequently improved by fine-tuning of the crystallization conditions. At this stage crystals of about 800x150x30µm in size can be obtained. They possess desirable visible characteristics of crystals including optical clarity, smooth facecs and sharp edges. Crystals rotate plane polarized light reflecting their well internal organization. Unfortunately relative slimness and sometimes cluster nature of the produced crystals complicates acquisition of high-resolution dataset and resolution of the structure. With some of obtained crystals diffraction to a resolution up to 4Å was observed.
Background:
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.
Methods:
In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.
Results:
We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.
Conclusions:
Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.
Terpenoids are major subcomponents in aroma substances which harbor sedative physiological potential. We have demonstrated that various monoterpenoids such as the acyclic linalool enhance GABAergic currents in an allosteric manner in vitro upon overexpression of inhibitory α1β2 GABA\(_{A}\) receptors in various expression systems. However, in plants or humans, i.e., following intake via inhalation or ingestion, linalool undergoes metabolic modifications including oxygenation and acetylation, which may affect the modulatory efficacy of the generated linalool derivatives. Here, we analyzed the modulatory potential of linalool derivatives at α1β2γ2 GABA\(_{A}\) receptors upon transient overexpression. Following receptor expression control, electrophysiological recordings in a whole cell configuration were used to determine the chloride influx upon co-application of GABA EC\(_{10-30}\) together with the modulatory substance. Our results show that only oxygenated linalool metabolites at carbon 8 positively affect GABAergic currents whereas derivatives hydroxylated or carboxylated at carbon 8 were rather ineffective. Acetylated linalool derivatives resulted in non-significant changes of GABAergic currents. We can conclude that metabolism of linalool reduces its positive allosteric potential at GABAA receptors compared to the significant potentiation effects of the parent molecule linalool itself.
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
Leukemia inhibitory factor (LIF) and Ciliary Neurotrophic factor (CNTF) are members of the interleukin-6 family of cytokines, defined by use of the gp130 molecule as an obligate receptor. In the murine experimental autoimmune encephalomyelitis (EAE) model, antagonism of LIF and genetic deletion of CNTF worsen disease. The potential mechanism of action of these cytokines in EAE is complex, as gp130 is expressed by all neural cells, and could involve immuno-modulation, reduction of oligodendrocyte injury, neuronal protection, or a combination of these actions. In this study we aim to investigate whether the beneficial effects of CNTF/LIF signalling in EAE are associated with axonal protection; and whether this requires signalling through oligodendrocytes. We induced MOG\(_{35-55}\) EAE in CNTF, LIF and double knockout mice. On a CNTF null background, LIF knockout was associated with increased EAE severity (EAE grade 2.1\(\pm\)0.14 vs 2.6\(\pm\)0.19; P<0.05). These mice also showed increased axonal damage relative to LIF heterozygous mice, as indicated by decreased optic nerve parallel diffusivity on MRI (1540\(\pm\)207 \(\mu\)m\(^2\)-/s vs 1310\(\pm\)175 \(\mu\)m\(^2\)-/s; P<0.05), and optic nerve (-12.5%) and spinal cord (-16%) axon densities; and increased serum neurofilament-H levels (2.5 fold increase). No differences in inflammatory cell numbers or peripheral auto-immune T-cell priming were evident. Oligodendrocyte-targeted gp130 knockout mice showed that disruption of CNTF/LIF signalling in these cells has no effect on acute EAE severity. These studies demonstrate that endogenous CNTF and LIF act centrally to protect axons from acute inflammatory destruction via an oligodendrocyte-independent mechanism.
TRAIL/APO-2L (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand) ist ein Apoptose-induzierendes Mitglied der TNF-Superfamilie (TNF-SF). Bislang sind zwei humane TRAIL-Todesrezeptoren, TRAIL-R1 und TRAIL-R2, bekannt, die zur TNF-Rezeptor-Superfamilie gehören. TRAIL induziert Apoptose in einer Vielzahl von Tumorzelllinien, wohingegen die meisten primären Zellen resistent gegenüber TRAIL sind. In präklinischen Studien mit Mäusen und nichthumanen Primaten wurde keine systemische Toxizität von TRAIL nachgewiesen. Diese Beobachtungen haben beträchtliches Interesse an dem Einsatz von TRAIL zur Tumortherapie geweckt. Über die physiologische Rolle von TRAIL ist jedoch noch wenig bekannt. Das Ziel dieser Arbeit war, Werkzeuge zum Studium des Apoptose-induzierenden TRAIL-Systems in Mäusen zu etablieren. Zunächst mussten das oder die murinen Homologe der beiden Apoptose-induzierenden TRAIL-Rezeptoren identifiziert werden. Dazu wurden murine TRAIL-bindende Proteine biochemisch über 2D-Gelanalysen identifiziert. Anhand einer Sequenzinformation aus einer Datenbank wurde ein muriner TRAIL-Rezeptor kloniert, der aufgrund seines biochemisch bestimmten Molekulargewichts p54_mTRAIL-R genannt wurde. Der Sequenzvergleich sowie die Funktionsanalyse von p54_mTRAIL-R ergab, dass dieser Rezeptor das funktionelle murine Homolog zu den humanen TRAIL-Todesrezeptoren TRAIL-R1 und TRAIL-R2 ist. So war p54_mTRAIL-R ebenfalls in der Lage, nach Überexpression Caspase-abhängig Apoptose zu induzieren. Wie die Transkripte der humanen TRAIL-Todesrezeptoren wurden die Transkripte von p54_mTRAIL-R in allen untersuchten Geweben detektiert. Es wurde ein lösliches p54_mTRAIL-R:Fc-Fusionsprotein hergestellt, welches zur TRAIL-Inaktivierung in vivo und in vitro verwendet werden kann. Um die physiologische Rolle des p54_mTRAIL-Rs in vivo studieren zu können, sollten mTRAIL-R-defiziente Mäuse generiert werden. Zur Modifikation des für p54_mTRAIL-R kodierenden tar-Locus wurde das Gen kloniert und charakterisiert. Um eine durch die Gendefizienz hervorgerufene eventuelle Letalität oder sekundäre kompensierende Effekte zu vermeiden, wurden mit Hilfe des Cre/loxP-Systems und des Flp/FRT-Systems konditionale p54_mTRAIL-R defiziente Mäuse hergestellt. Die Werkzeuge, die in dieser Arbeit generiert wurden, wie lösliches p54_mTRAIL-R:Fc Fusionsprotein und konditionale p54_mTRAIL-R defiziente Mäuse, können nun in vivo für die Erforschung der physiologischen Rolle des TRAIL-Systems sowie seines Potentials und dessen Grenzen bei der Tumortherapie benutzt werden.
Die Deletion des AT2-Rezeptors (AT2-KO) führt zu erhöhter Blutdruckempfindlichkeit und vaskulärer Hypertrophie durch Aktivitätszunahhme der P70S6-Kinase. Die Vasodilatation von Blutgefäßen wird maßgeblich durch beta1-adrenerge Rezeptoren vermittelt. Die Deletion von alpha2-adrenergen Rezeptoren (alpha2-KO) führt zur Entwicklung einer Herzinsuffizienz nach Aortenstenose. Der Mortalitätanstieg ist mit erhöhten Plasmanoradrenalin-Spiegeln (a2A-KO), bzw. Plasmaadrenalin-Spiegeln (a2C-KO) assoziiert.